Preclinical Evaluation of Anti-CD38 Therapy in Mature T-cell Neoplasms

Authors

Colleen Isabelle, Thomas Jefferson UniversityFollow
William Johnson
Kathleen McConnell, Thomas Jefferson University
Ashley Vogel, Thomas Jefferson University
Jonathan Brammer
Amy Boles, Thomas Jefferson UniversityFollow
Robyn Keller, Thomas Jefferson University
Paola Sindaco, Thomas Jefferson UniversityFollow
Liam Nisenfeld, Thomas Jefferson UniversityFollow
Guldeep Uppal, Thomas Jefferson UniversityFollow
Neda Nikbakht, Thomas Jefferson UniversityFollow
Bruno Calabretta, Thomas Jefferson UniversityFollow
Patrizia Porazzi
Jerald Gong, Thomas Jefferson UniversityFollow
Nitin Chakravarti, Thomas Jefferson UniversityFollow
Pierluigi Porcu, Thomas Jefferson UniversityFollow
Anjali Mishra, Thomas Jefferson UniversityFollow

Document Type

Letter to the Editor

Publication Date

7-25-2023

Comments

This article is the author's final published version, originally published, in Blood Advances, Volume 7, Issue 14, July 2023, Pages 3637 - 3641.

The published version is available at https://doi.org/10.1182/bloodadvances.2023009807.

Copyright © 2023 by The American Society of Hematology

Recommended Citation

Isabelle, Colleen; Johnson, William; McConnell, Kathleen; Vogel, Ashley; Brammer, Jonathan; Boles, Amy; Keller, Robyn; Sindaco, Paola; Nisenfeld, Liam; Uppal, Guldeep; Nikbakht, Neda; Calabretta, Bruno; Porazzi, Patrizia; Gong, Jerald; Chakravarti, Nitin; Porcu, Pierluigi; and Mishra, Anjali, "Preclinical Evaluation of Anti-CD38 Therapy in Mature T-cell Neoplasms" (2023). Kimmel Cancer Center Faculty Papers. Paper 117.
https://jdc.jefferson.edu/kimmelccfp/117

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

PubMed ID

36989058

Language

English